Resistant Hypertension. Target Aldosterone. Transform Care š
Dr RR Baliga's "Got Knowledge Doc" Podkast
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Resistant hypertension remains one of the most stubborn challenges in cardiovascular medicine.
The Bax24 phase 3 trial, published in The Lancet (2026), evaluated baxdrostat, a selective aldosterone synthase inhibitor, in patients already receiving multiple antihypertensive agents.
Key findings:
ā¢ ā16.6 mmHg reduction in 24-hour ambulatory SBP
ā¢ ā14.0 mmHg placebo-corrected difference (p
ā¢ 71% achieved BP control (
ā¢ Acceptable safety profile, with hyperkalemia in 3%
These data highlight the growing importance of aldosterone dysregulation in resistant hypertension and suggest that targeted aldosterone synthase inhibition may represent a new therapeutic frontier.
Reference: Azizi M et al. Effect of Baxdrostat on Ambulatory Blood Pressure in Resistant Hypertension (Bax24). Lancet 2026.